GSK melanoma drug shows promise in early trial
May 18th, 2012More info…
LONDON (Reuters) – An experimental cancer drug developed by Britain’s GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday.
